Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1.

Eitemau Tebyg

• Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720.
  gan: Balzarini, J, et al.
  Cyhoeddwyd: (1994)
• Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors
  gan: Balzarini, Jan, et al.
  Cyhoeddwyd: (1996)
• Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants.
  gan: Balzarini, J, et al.
  Cyhoeddwyd: (1994)
• Chemical crosslinking of the subunits of HIV-1 reverse transcriptase.
  gan: Debyser, Z., et al.
  Cyhoeddwyd: (1996)
• 1,1,3-Trioxo-2H,4H-Thieno[3,4-e][1,2,4]Thiadiazine (TTD) Derivatives: a New Class of Nonnucleoside Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Inhibitors with Anti-HIV-1 Activity
  gan: Witvrouw, M., et al.
  Cyhoeddwyd: (1998)